AU2017382888B2 - Ectonucleotidase inhibitors and methods of use thereof - Google Patents

Ectonucleotidase inhibitors and methods of use thereof Download PDF

Info

Publication number
AU2017382888B2
AU2017382888B2 AU2017382888A AU2017382888A AU2017382888B2 AU 2017382888 B2 AU2017382888 B2 AU 2017382888B2 AU 2017382888 A AU2017382888 A AU 2017382888A AU 2017382888 A AU2017382888 A AU 2017382888A AU 2017382888 B2 AU2017382888 B2 AU 2017382888B2
Authority
AU
Australia
Prior art keywords
amino
fluoro
methoxy
chloro
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017382888A
Other languages
English (en)
Other versions
AU2017382888A1 (en
Inventor
Roland Joseph Billedeau
Lijing Chen
Jim Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antengene Therapeutics Ltd
Original Assignee
Antengene Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Therapeutics Ltd filed Critical Antengene Therapeutics Ltd
Publication of AU2017382888A1 publication Critical patent/AU2017382888A1/en
Application granted granted Critical
Publication of AU2017382888B2 publication Critical patent/AU2017382888B2/en
Assigned to ANTENGENE THERAPEUTICS LIMITED reassignment ANTENGENE THERAPEUTICS LIMITED Request for Assignment Assignors: CALITHERA BIOSCIENCES, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017382888A 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof Active AU2017382888B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662437935P 2016-12-22 2016-12-22
US201662437915P 2016-12-22 2016-12-22
US62/437,935 2016-12-22
US62/437,915 2016-12-22
US201762555791P 2017-09-08 2017-09-08
US62/555,791 2017-09-08
PCT/US2017/067980 WO2018119284A1 (en) 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017382888A1 AU2017382888A1 (en) 2019-06-20
AU2017382888B2 true AU2017382888B2 (en) 2021-12-23

Family

ID=62627279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017382888A Active AU2017382888B2 (en) 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Country Status (12)

Country Link
US (3) US10570167B2 (enExample)
EP (1) EP3558998A4 (enExample)
JP (1) JP7138351B2 (enExample)
KR (1) KR102638592B1 (enExample)
CN (1) CN110402249A (enExample)
AU (1) AU2017382888B2 (enExample)
CA (1) CA3047988A1 (enExample)
IL (1) IL267291B2 (enExample)
MX (1) MX383880B (enExample)
NZ (1) NZ754171A (enExample)
TW (1) TWI766923B (enExample)
WO (1) WO2018119284A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7125144B2 (ja) * 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
CA3047988A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
EP3661966A4 (en) 2017-07-31 2021-07-21 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES AND METHODS OF USE OF ANTI-CD39 ANTIBODIES
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
IL304348B2 (en) 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
CN112888696B (zh) 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法
AU2020239048B2 (en) 2019-03-12 2025-10-16 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
KR20210144821A (ko) 2019-03-29 2021-11-30 아르커스 바이오사이언시즈 인코포레이티드 규명된 아데노신 지문을 이용한 암의 치료방법
US20220251134A1 (en) 2019-06-14 2022-08-11 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
CA3143496A1 (en) * 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
CA3159248C (en) 2019-10-30 2024-05-28 Oric Pharmaceuticals, Inc. Cd73 inhibitors
JP7381913B2 (ja) * 2021-10-13 2023-11-16 ダイキン工業株式会社 有害生物防除組成物
US12103943B2 (en) * 2021-10-26 2024-10-01 Southern Research Institute Development of novel clofarabine analogs for cancer therapy
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085994A1 (en) 1991-04-24 1992-10-25 Shinji Sakata 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives
WO1994010128A1 (en) 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
WO1996018636A1 (en) * 1994-12-13 1996-06-20 Taiho Pharmaceutical Co., Ltd. 3'-substituted nucleoside derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
US8603998B2 (en) 2007-11-07 2013-12-10 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
CN103209970B (zh) 2010-07-08 2016-08-24 生命科技公司 原位化学发光底物和测定
WO2012151142A2 (en) 2011-05-03 2012-11-08 Life Technologies Corporation Flash and glow 1,2-dioxetanes
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017079195A1 (en) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
CA3151595A1 (en) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
JP7125144B2 (ja) 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
CA3047988A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CN112888696B (zh) 2018-06-21 2024-04-16 德琪医疗有限公司 外核苷酸酶抑制剂及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
IL267291B (en) 2022-12-01
EP3558998A4 (en) 2020-06-10
NZ754171A (en) 2022-12-23
TWI766923B (zh) 2022-06-11
US20180186827A1 (en) 2018-07-05
CN110402249A (zh) 2019-11-01
WO2018119284A1 (en) 2018-06-28
KR20190114972A (ko) 2019-10-10
US11034715B2 (en) 2021-06-15
CA3047988A1 (en) 2018-06-28
MX383880B (es) 2025-03-14
BR112019012327A2 (pt) 2019-11-19
US20200223882A1 (en) 2020-07-16
TW201834665A (zh) 2018-10-01
US20230002437A1 (en) 2023-01-05
US10570167B2 (en) 2020-02-25
JP2020504735A (ja) 2020-02-13
IL267291B2 (en) 2023-04-01
JP7138351B2 (ja) 2022-09-16
MX2019007243A (es) 2019-09-06
EP3558998A1 (en) 2019-10-30
IL267291A (en) 2019-08-29
AU2017382888A1 (en) 2019-06-20
KR102638592B1 (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
AU2017382888B2 (en) Ectonucleotidase inhibitors and methods of use thereof
US11208414B2 (en) Ectonucleotidase inhibitors and methods of use thereof
US12421273B2 (en) Ectonucleotidase inhibitors and methods of use thereof
KR102902754B1 (ko) 엑토뉴클레오티다제 저해제 및 이의 사용 방법
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
EA046381B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
NZ790347A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ANTENGENE THERAPEUTICS LIMITED

Free format text: FORMER OWNER(S): CALITHERA BIOSCIENCES, INC.